Doctor of Philosophy

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Retrieved on: 
Thursday, May 2, 2024
TSX, Doctor of Philosophy, Esophagus, MPH, Immunoglobulin E, Allergic rhinitis, Asthma, Eosinophilic esophagitis, Pharmaceutical industry

VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.

Key Points: 
  • VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.
  • The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw.
  • The Clinical Advisory Board will work closely with Eupraxia as it continues its development of EP-104GI for eosinophilic esophagitis ("EoE"), which is currently in a Phase 1b/2a clinical trial.
  • "The formation of our Gastrointestinal Clinical Advisory Board comes at an exciting time for our Company, as we continue to generate clinical evidence in support of EP-104GI for the treatment of eosinophilic esophagitis," said Mark Kowalski, MD, PhD, Chief Medical Officer of Eupraxia.

Fred Ghodoosi Joins L&F Brown as Senior Litigation Counsel

Retrieved on: 
Thursday, May 2, 2024
Yale Law School, Law, The National, George Washington University, Florida International University, Fortune 500, Doctor of Philosophy, Artificial intelligence, University, P.C, Morgan State University, University of California, Berkeley, FINRA, Faculty, Economics, Knowledge

LOS ANGELES, May 1, 2024 /PRNewswire-PRWeb/ -- L&F Brown, P.C., a law firm serving the needs of Fintech, Legaltech and other innovative companies, has announced the addition of Fred Ghodoosi as Senior Litigation Counsel. Throughout his career, Ghodoosi has been counsel for Fortune 100 companies, high net worth individuals and tech startups. He has established a reputation for winning big against the big firms.

Key Points: 
  • Throughout his career, Ghodoosi has been counsel for Fortune 100 companies, high net worth individuals and tech startups.
  • "Fred made an impact from day one at L&F Brown," said founding Partner Curt Brown.
  • Ghodoosi joins the firm after serving as an arbitrator in high stakes financial disputes for the Financial Industry Regulatory Authority (FINRA).
  • "I chose L&F Brown because they've been successful through strategic litigation," said Ghodoosi.

Emergency Departments Frequently Miss Signs of Epilepsy in Children

Retrieved on: 
Wednesday, May 1, 2024
Roger Hawkins (drummer), University, Stroke, Seizure, Hospital, Risk, Death, DSM-IV codes, NYU Langone Health, Partnership, Doctor of Philosophy, Research, Emotion, NYU, History, Knowledge, Patient, Physician, Neurology, Epilepsy, Child, Diagnosis, Einstein Medical Center Philadelphia, Brain, Panic, Amnesia, Anxiety, Pharmaceutical industry

The work focuses on "nonmotor" seizures, which cause children to "zone out" and stare into space or fidget.

Key Points: 
  • The work focuses on "nonmotor" seizures, which cause children to "zone out" and stare into space or fidget.
  • To be diagnosed with the condition, a patient must have experienced a minimum of two seizures with no apparent cause.
  • Their analysis showed that emergency department physicians correctly identified only 33% of first-time nonmotor seizures, compared with 81% of first-time motor seizures.
  • According to the United States Centers for Disease Control and Prevention, epilepsy is one of the most common brain disorders in children, affecting 470,000 under age 17.

COGNIZANT REPORTS FIRST QUARTER 2024 RESULTS

Retrieved on: 
Wednesday, May 1, 2024
Cloud, Cognizant, PEAK, AI, FCC, Google Cloud, Partnership, Facet, HFS, Intelligence, Shopify, Culture, Fortune (magazine), NVIDIA, Intellectual property, Drug discovery, GAAP, Telstra, Fraud, Machine learning, LexisNexis, Health, Airline, Workforce, FICO, Performance, IDC, Nextgen, ServiceNow, Doctor of Philosophy, Insurance, Pon Holdings, Artificial intelligence, Assessment, Engineering, Automation, First officer (aviation), Microsoft, EPS, CPG, Science, Patient, Acquisition, CNO, Share repurchase, Telecommunications, Adjustment, Growth

The Company repurchased 1.4 million shares for $110 million during the first quarter under its share repurchase program.

Key Points: 
  • The Company repurchased 1.4 million shares for $110 million during the first quarter under its share repurchase program.
  • In April 2024, the Company declared a quarterly cash dividend of $0.30 per share for shareholders of record on May 20, 2024.
  • The conference call will also be available live on the Investor Relations section of the Cognizant website at http://investors.cognizant.com .
  • An earnings supplement will also be available on the Cognizant website at the time of the conference call.

Hartford Hospital's Institute of Living Launches Center for Research on Racial Trauma and Community Healing

Retrieved on: 
Wednesday, May 1, 2024
Research, MD, Partnership, Doctor of Philosophy, Parent, The Institute of Living, Intelligence, Psychiatry, Health information management, Racial trauma, Hartford Hospital, Hospital

HARTFORD, Conn., May 1, 2024 /PRNewswire/ -- Hartford HealthCare's Institute of Living at Hartford Hospital launched the Center for Research on Racial Trauma and Community Healing, a one-of-a-kind research center.

Key Points: 
  • HARTFORD, Conn., May 1, 2024 /PRNewswire/ -- Hartford HealthCare's Institute of Living at Hartford Hospital launched the Center for Research on Racial Trauma and Community Healing, a one-of-a-kind research center.
  • "With everything that we continue to endure, we wanted to prioritize the topics of racial trauma and community healing.
  • Representatives from Hartford HealthCare, Hartford Mayor Arunan Arulampalam, local community and civic organizations, and residents held a community conversation Tuesday at the Artists Collective in Hartford to address long standing issues in the Hartford community and to celebrate what this Center will mean.
  • For more information on the Center for Research on Racial Trauma and Community Healing, visit https://instituteofliving.org/health-professionals/center-for-racial-trauma

ZEEL OFFERS HOSPITALS THE OPPORTUNITY TO REWARD NURSES FOR NATIONAL NURSES WEEK

Retrieved on: 
Wednesday, May 1, 2024
Hospital, Massage, Health, Nursing, Doctor of Philosophy, Insomnia, Neck pain, Science, Denver Health Medical Center, Patient, RN, Absenteeism

NEW YORK, May 1, 2024 /PRNewswire/ -- Zeel, the leading tech-enabled platform for bringing health and wellness services to the home or office, is proud to partner with hospitals and medical practices across the country to reward nurses during National Nurses Week, May 6-12, 2024.

Key Points: 
  • NEW YORK, May 1, 2024 /PRNewswire/ -- Zeel, the leading tech-enabled platform for bringing health and wellness services to the home or office, is proud to partner with hospitals and medical practices across the country to reward nurses during National Nurses Week, May 6-12, 2024.
  • Zeel offers the benefit of chair massage in the hospital or healthcare setting and/or the gift of an at-home massage to help reward nurses for everything they do.
  • "We have a proud history of nursing at Denver Health that started with the Colorado Training School for Nurses, the first school for nurses west of the Mississippi.
  • He continued, "We're seeing interest in the programs to show nurses they are deeply valued, not just during National Nurses Week, but every day throughout the year."

EverGlade Consulting Welcomes New Managing Director, Joe Larsen

Retrieved on: 
Wednesday, May 1, 2024
Doctor of Philosophy, Public, University, Locus Biosciences, Outline of health sciences, Safety, Biomedical Research, Research, Development, Project, Immunology, Biotechnology, Division, Growth, Strategic planning, Medical device

HOUSTON, May 1, 2024 /PRNewswire/ -- EverGlade Consulting is pleased to announce the appointment of Dr. Joe Larsen as Managing Director, effective April 2024. Dr. Larsen brings with him a rich background in biomedical research and healthcare policy, significantly enhancing EverGlade's capabilities in navigating complex regulatory and scientific challenges. His impressive career spans over two decades, during which he has held pivotal roles in both governmental and private sectors.

Key Points: 
  • HOUSTON, May 1, 2024 /PRNewswire/ -- EverGlade Consulting is pleased to announce the appointment of Dr. Joe Larsen as Managing Director, effective April 2024.
  • Dr. Larsen brings with him a rich background in biomedical research and healthcare policy, significantly enhancing EverGlade's capabilities in navigating complex regulatory and scientific challenges.
  • Prior to joining EverGlade, Dr. Larsen spent five years at biotechnology companies developing anti-infective drugs for the treatment of antibiotic resistant bacteria.
  • — Eric Jia-Sobota, Founder and National Consulting Leader
    Dr. Larsen's addition to the EverGlade team underscores the firm's commitment to leadership excellence and its dedication to providing cutting-edge solutions in healthcare consulting.

Somite Therapeutics to Present at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Retrieved on: 
Wednesday, May 1, 2024
Doctor of Philosophy, AI, Cell, Poster, Diabetes, MD, Computational biology, B cell, PSC, Differentiable function, Obesity, SVP, Muscular dystrophy, Developmental biology, Gene, Society, MUSCULAR, Cartilage, Therapy, Translation, MIT, Pharmaceutical industry

BOSTON, May 1, 2024 /PRNewswire/ -- Somite Therapeutics, a tech-bio company leveraging big data and AI to introduce novel cell replacement therapies, today announced that the Company will present a poster at the upcoming American Society of Cell and Gene Therapy (ASGCT) Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Key Points: 
  • [[To comply with academic institution guidelines, the founders' academic affiliations and roles are listed only at the end of the statement.]]
  • BOSTON, May 1, 2024 /PRNewswire/ -- Somite Therapeutics , a tech-bio company leveraging big data and AI to introduce novel cell replacement therapies, today announced that the Company will present a poster at the upcoming American Society of Cell and Gene Therapy (ASGCT) Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
  • Founded in October 2023, Somite is building AI foundation models to produce human tissue at scale for cell therapies.
  • These therapies have the potential to treat a wide range of diseases that involve the loss or deficiency of cell populations, such as diabetes, obesity, and muscular dystrophies.

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
Wednesday, May 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

Verywell Mind Announces Winners of Second Annual Verywell Mind 25 to Kickoff Mental Health Awareness Month

Retrieved on: 
Wednesday, May 1, 2024
Education, LPC, Doctor of Psychology, LMHC, Policy, Doctor of Philosophy, Verywell, Mental health, LMSW, Mental, SVP, Work, Nursing

NEW YORK, May 1, 2024 /PRNewswire/ -- Today, Verywell Mind, one of the largest mental health sites, announced its second annual Verywell Mind 25. The awards program recognizes influential mental health advocates and their impact on policy, community engagement, and awareness.

Key Points: 
  • NEW YORK, May 1, 2024 /PRNewswire/ -- Today, Verywell Mind , one of the largest mental health sites, announced its second annual Verywell Mind 25 .
  • The awards program recognizes influential mental health advocates and their impact on policy, community engagement, and awareness.
  • To select this year's honorees, Verywell Mind editors, along with the brand's expert review board, gathered and evaluated nearly 80 nominees across mental health experts, non-profit founders, educators, authors and more.
  • To learn more about the Verywell Mind 25 and read about this year's winners, visit here .